Press release
Dysmenorrhea Treatment Market size and forecast, 2016-2026
Dysmenorrhea is a medical terminology used for menstrual pains in which the female encounters severe cramps in her lower abdomen which may extend to the lower legs and back. Most women begin having dysmenorrhea during adolescence, usually within four to five years of first menstrual period. Prostaglandins are chemicals that are formed in the lining of the uterus during menstruation. These prostaglandins cause muscle contractions in the uterus, which cause pain and decrease blood flow and oxygen to the uterus. A wide variety of underlying condition can contribute to menstrual disorders. To pinpoint the cause, physician generally rely on the patient’s medical history, physical examination, and laboratory test. This determines the exact cause of menstrual disorder and helps the physician to plan appropriate treatment. This has grabbed the attention of dysmenorrhea drug manufacturers to develop and commercialize more effective medicines to treat dysmenorrhea.Dysmenorrhea Treatment Market: Drivers and Restraints
Increasing incidence of dysmenorrhea, high awareness level and growing concern about dysmenorrhea among females from developed countries, involvement of companies for developing innovative drugs, and government campaigns with respect to women healthcare are effectively endorsing the growth of dysmenorrhea treatment market. However, side effect and complications of long term treatment, substantial morbidity of dysmenorrhea which leads to inadequate treatment, and traditional values of families would hinder the growth of dysmenorrhea treatment market.
Dysmenorrhea Treatment Market: Segmentation
The global dysmenorrhea treatment market is segmented based type of disease, and therapeutic class.
Based type of diseases, the global dysmenorrhea market is segmented into the following:
Primary dysmenorrhea
Secondary dysmenorrhea
Endometriosis
Adenomyosis
Uterine myomas
Endometrial polyps
Cervical stenosis
Obstructive malformations of genital tract
Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1312
Based on therapeutic class, the global dysmenorrhea treatment market is segmented into the following:
Non-hormonal medical treatment
Non-steroidal anti-inflammatory drugs (NSAIDs)
Non-selective NSAIDs
COX-2 inhibitors
Transdermal glyceryl trinitrate
Over-the-counter (OTC) medications
Hormonal medicine treatment
Combined oral contraceptive
Progestin regimens
Levonorgestrel intrauterine system (LN-IUS)
Surgical options
Laparoscopy
Hysterectomy
Presacral neurectomy
Laparoscopic uterosacral nerve ablation (LUNA)
Intrauterine device (IUD)
Dysmenorrhea Treatment Market: Overview
By non-hormonal medical treatment, NSAID’s such as Ibuprofen and Naproxen, are most commonly used drugs for the treatment of dysmenorrhea and hold prominent share owing to its lower cost and easy availability. COX-2 inhibitors have also proven effective in relieving pain, and would gain prominence in developed countries. Physicians also prescribe hormonal medicine treatment such as contraceptive pills to regularize the menstrual bleeding will gain good market share in emerging countries.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1312
Dysmenorrhea Treatment Market: Region-wise Outlook
Geographically, the North America accounts for the largest market share followed by Europe, in terms revenues and research activities. In addition. APEI market is also expected to grow significantly in the coming years owing to support of government and non-profit organizations in awareness campaigns, growing number of patients suffering with dysmenorrhea, and high disposable income.
Dysmenorrhea Treatment Market: Key Players
Key companies operational in dysmenorrhea treatment market are Novartis Pharmaceuticals Corporation, Merck, Inc., Bayer Schering Pharma AG, Vanita Therapeutics, Alvogen, Pfizer, Inc., Roche Laboratories, Taj Pharmaceuticals, Ltd., Sanofi, Terramedic, Inc., and others.
ABOUT US:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.
CONTACT:
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Press: press@futuremarketinsights.com
Website: www.futuremarketinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dysmenorrhea Treatment Market size and forecast, 2016-2026 here
News-ID: 571859 • Views: …
More Releases from Future Market Insights

Global Pectin Market Poised for Steady Growth as Innovation, Sustainability, and …
The global pectin market is entering a dynamic growth phase, with its valuation projected to rise from USD 1,125.9 million in 2025 to USD 2,074.2 million by 2035, advancing at a CAGR of 6.3%. Unlike many markets driven by broad consumer preferences, the pectin industry's trajectory is fueled by technological advancements, targeted product development, and a rising demand for sustainable and natural solutions. Both established manufacturers and emerging players are…

Isomalto-oligosaccharide Market Poised for Growth as Health-Conscious Consumers …
The global Isomalto-oligosaccharide (IMO) market is entering a period of strong growth, fueled by changing dietary preferences, rising health awareness, and a surge in innovation among manufacturers. Valued at USD 86.8 million in 2025, the market is projected to nearly double, reaching USD 181.6 million by 2035 at a steady CAGR of 7.7%.
The momentum reflects a growing consumer shift toward healthier lifestyles, particularly as awareness around obesity, diabetes, and gut…

Ashwagandha Extract Market Set for Strong Growth, Driven by Health Awareness, Sc …
The global Ashwagandha Extract market is on a dynamic growth path, projected to rise from USD 815.7 million in 2025 to USD 1,787.2 million by 2035, achieving a CAGR of 8.2% over the forecast period. This momentum reflects a powerful convergence of consumer health awareness, scientific validation of Ashwagandha's benefits, and manufacturers-both established leaders and emerging players-introducing innovative formulations to capture growing demand.
The surge in demand comes at a time…

Taurine Market to Reach USD 954.8 Million by 2035, Backed by Expanding Use in He …
The global taurine market is on track for robust growth over the next decade, with demand rising from USD 476.4 million in 2025 to USD 954.8 million by 2035, representing a healthy CAGR of 7.2%. This expansion is fueled by taurine's growing role across health supplements, infant nutrition, functional foods, energy beverages, and pet health products.
Taurine, an amino acid long recognized for its cardiovascular, metabolic, and neurological benefits, is increasingly…
More Releases for Dysmenorrhea
Dysmenorrhea Market Share, Epidemiology, Analysis & Trends 2023-2033
Market Overview:
The dysmenorrhea market is expected to exhibit a CAGR of 5.67% during 2023-2033. The dysmenorrhea market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the market share of various therapies, and the market's performance in the seven major…
Dysmenorrhea - Drug Pipeline Landscape, 2022
Global Dysmenorrhea Market report from Global Insight Services is the single authoritative source of intelligence on Dysmenorrhea market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types, applications, and…
Dysmenorrhea - Drug Pipeline Landscape, 2022
Dysmenorrhea, also known as painful periods or menstrual cramps, is a common problem experienced by women during their reproductive years. It is estimated that 50-90% of women of reproductive age suffer from dysmenorrhea. The pain is usually felt in the lower abdomen and can range from mild to severe. The pain may begin one to two days before the start of menstru*tion and last for the first few days of…
Dysmenorrhea - Drug Pipeline Landscape, 2022
Dysmenorrhea, also known as painful periods or menstrual cramps, is a common problem experienced by women during their reproductive years. It is estimated that 50-90% of women of reproductive age suffer from dysmenorrhea. The pain is usually felt in the lower abdomen and can range from mild to severe. The pain may begin one to two days before the start of and last for the first few days of…
Dysmenorrhea Treatment Market: Market Intelligence and Market Trends
Dysmenorrhea is a medical terminology used for menstrual pains in which the female encounters severe cramps in her lower abdomen which may extend to the lower legs and back. Most women begin having dysmenorrhea during adolescence, usually within four to five years of first menstrual period. Prostaglandins are chemicals that are formed in the lining of the uterus during menstruation. These prostaglandins cause muscle contractions in the uterus, which cause…
Dysmenorrhea Treatment Survey and 2027 Foresight Report
Dysmenorrhea Treatment: Market Overview
Globally, more than 50% of post pubescent menstruating women are affected by dysmenorrhea, with 10–12% of them having severe dysmenorrhea with incapacitation for 1–3 days each month. Because young women constitute a significant percentage of the adult work force in the US, nearby 600 million working hours or 2 billion dollars are lost annually because of incapacitating dysmenorrhea if adequate relief is not provided. Women who continue…